Constellation Pharmaceuticals Inc
CNST
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
17% upsideUndervalued by 17% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-110,618,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.65 |
| Beta | 2.58 |
| Outstanding Shares | 47,838,738 |
Return
| Return on Equity | -37.36% |
|---|---|
| Return on Assets | -35.01% |
| Return on Invested Capital | -36.83% |
Valuation & Multiples
| P/E Ratio | -12.83 |
|---|---|
| PEG | -22.31 |
| Price to Sales | - |
| Price to Book Ratio | 4.86 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.8 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Constellation Pharmaceuticals Inc
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policies and tax credits for R&D, which are critical for biotech company valuations.
Allocates the specific discretionary funding for the NIH and FDA, directly impacting the resources available for biotech oversight and research grants.
Directly oversees the FDA and NIH; members have access to non-public information regarding drug approval processes and clinical trial standards.
Oversees patent law and intellectual property rights, which are the primary value drivers for biotechnology and pharmaceutical R&D.
Frequently investigates drug pricing and healthcare quality for the elderly, a key demographic for biotechnology products.